Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of “Reduce” from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have earned an average rating of “Reduce” from the fifteen analysts that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $214.00.

Several analysts have issued reports on the company. Redburn Atlantic assumed coverage on Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, September 20th. TD Cowen increased their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th.

Charles River Laboratories International Trading Down 3.3 %

Shares of NYSE:CRL opened at $183.16 on Thursday. The firm has a market capitalization of $9.37 billion, a price-to-earnings ratio of 22.92, a price-to-earnings-growth ratio of 5.00 and a beta of 1.38. The business’s 50 day moving average price is $194.33 and its 200-day moving average price is $202.55. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. Charles River Laboratories International has a 1 year low of $176.48 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter in the prior year, the firm earned $2.72 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. On average, equities research analysts forecast that Charles River Laboratories International will post 10.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CRL. Virtu Financial LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $601,000. State Street Corp lifted its stake in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after acquiring an additional 41,421 shares during the period. Quest Partners LLC boosted its holdings in shares of Charles River Laboratories International by 135,175.0% in the second quarter. Quest Partners LLC now owns 5,411 shares of the medical research company’s stock valued at $1,118,000 after acquiring an additional 5,407 shares in the last quarter. Neo Ivy Capital Management acquired a new position in shares of Charles River Laboratories International during the third quarter worth about $966,000. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in Charles River Laboratories International by 3.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock worth $22,060,000 after purchasing an additional 3,714 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).